Skip to main content
. 2015 Jan 26;36(4):507–516. doi: 10.1038/aps.2014.143

Figure 1.

Figure 1

Bigelovin inhibited IL-6–induced and constitutive activation of STAT3 in human tumor cell lines. (A) The structure of bigelovin. (B) HepG2/STAT3 cells were pretreated with bigelovin at the indicated concentrations for 1 h, and luciferase activity was measured following IL-6 stimulation (20 ng/mL) for 5 h. n=3 experiments. Mean±SEM. cP<0.01 vs control. (C) HepG2/STAT3 cells were treated with the indicated concentrations of bigelovin for 6 h. Cell viability was determined by MTT assay. (D) HeLa cells were pretreated with bigelovin at the indicated concentrations for 1 h before IL-6 stimulation (10 ng/mL) for 15 min. Whole-cell lysates were processed for Western blot analysis and probed with the indicated antibodies. Tubulin served as a loading control. (E) HeLa cells were pretreated with 10 μmol/L bigelovin for various lengths of time (0–120 min) before stimulation with IL-6 (10 ng/mL) for 10 min. Whole-cell lysates were subjected to Western blot analysis. (F) MDA-MB-468 and A549 cells were treated with bigelovin at the indicated concentrations for 1 h. Whole-cell lysates were subjected to Western blot analysis.